Currently, the driver genes recommended in NCCN guidelines for advanced NSCLC detection include EGFR, ALK, KRAS, RET, ROS‐1, ERBB2, BRAF, and c‐MET, among which patients with EGFR, ALK, and ROS1 positive4, 6, 20 are recommended to use first‐line corresponding targeted drug therapy. Here, ERBB2 is linked to non-small cell lung carcinoma.